Patent Case Summaries | Week Ending April 17, 2026

Why It Matters

These rulings sharpen key patent doctrines—extraterritoriality, on‑sale bar, and written‑description standards—affecting how tech and pharma firms assess infringement risk and draft claims.

Key Takeaways

• Federal Circuit reversed Intel noninfringement summary judgments on extraterritoriality.
• Court rejected VLSI’s doctrine‑of‑equivalents disclaimer, allowing claim scope.
• Federal Circuit upheld on‑sale invalidity for Powerteq based on PP3 device.
• Court clarified source‑code commands are non‑hearsay in patent litigation.
• Federal Circuit remanded Teva‑Lilly case, finding adequate written description and enablement.

Pulse Analysis

The Federal Circuit’s reversal of Intel’s non‑infringement rulings underscores a growing willingness to enforce contractual extraterritoriality stipulations in patent cases. By treating a 70% U.S. nexus clause as controlling, the court signals that multinational chip makers must carefully align product distribution with any pre‑trial agreements. The decision also tightens the doctrine of equivalents, rejecting overly narrow prosecution‑disclaimer arguments and preserving broader claim coverage for multicore processor technologies.

In the Definitive Holdings v. Powerteq case, the court affirmed that the on‑sale bar applies even when the sold device does not explicitly disclose the patented invention’s inner workings. The reliance on authenticated sales records and the classification of source‑code commands as non‑hearsay provide a clearer evidentiary roadmap for litigators. This clarification benefits hardware and software vendors by confirming that public sales of functional equivalents can trigger invalidity, prompting more rigorous prior‑art searches and documentation of product capabilities.

The Teva‑Lilly opinion revitalizes written‑description and enablement standards, especially for biotech patents covering therapeutic antibodies. By emphasizing that a patent need only disclose a representative genus or functional use, the court eases the burden on innovators who develop families of biologics. This approach encourages broader claim strategies while still demanding sufficient detail to guide skilled artisans. Pharmaceutical companies can now leverage these nuances to protect antibody platforms without over‑detailing each variant, balancing robust protection with regulatory practicality.